1-(4-bromo-3,5-dimethyl-pyridin-2-ylmethyl)-4-chloro-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine | 848697-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-bromo-3,5-dimethyl-pyridin-2-ylmethyl)-4-chloro-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine
• 英文别名: 1-[(4-Bromo-3,5-dimethylpyridin-2-yl)methyl]-4-chloro-3-phenylpyrazolo[3,4-d]pyrimidin-6-amine
• CAS: 848697-32-5
• 化学式: C₁₉H₁₆BrClN₆
• 分子量: 443.733
• InChiKey: PEYKEUAXBQDOKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  82.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pyrazolopyrimidines and related analogs as HSP90-inhibitors
  申请人：Kasibhatla Rao Srinivas

  公开号：US20050119282A1

  公开（公告）日：2005-06-02

  Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  本文描述了吡唑吡咯啉和相关类似物，证明或预测其在治疗和预防各种HSP90介导的疾病，例如增生性疾病中作为HSP90抑制剂的效用。同时还描述和声明了这些化合物的合成方法和用途。
• Deazapurine derivatives as HSP90-Inhibitors
  申请人：Conforma Therapeutics Corporation

  公开号：EP2145888A1

  公开（公告）日：2010-01-20

  Heterobicyclic compounds of formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agent. Method of synthesis and use of such compounds are also described.

  描述并证明了式 I 的杂双环化合物作为热休克蛋白 90（HSP90）抑制剂的实用性。还描述了合成和使用此类化合物的方法。
• US7148228B2
  申请人：——

  公开号：US7148228B2

  公开（公告）日：2006-12-12
• [EN] ANTI-TUMOR METHODS USING MULTI DRUG RESISTANCE INDEPENDENT SYNTHETIC HSP90 INHIBITORS<br/>[FR] METHODES ANTITUMORALES DANS LESQUELLES SONT UTILISES DES INHIBITEURS DE HSP90 DE SYNTHESE INDEPENDANTS DE LA MULTIRESISTANCE AUX MEDICAMENTS
  申请人：CONFORMA THERAPEUTICS CORP

  公开号：WO2007035963A2

  公开（公告）日：2007-03-29

  [EN] The present invention provides a method of treating an individual having an HSP90 mediated disorder comprising administering to said individual a pharmaceutical composition comprising a pharmaceutically effective amount of a synthetic heterocyclic HSP90 inhibitor, wherein the activity of the HSP90 inhibitor is substantially independent of multi drug resistance. In one embodiment, the activity of the HSP90 inhibitor is substantially independent of P-gp and MRP expression.
  [FR] La présente invention concerne une méthode destinée au traitement d'un individu atteint d'un trouble induit par HSP90, consistant à administrer audit individu une composition pharmaceutique comprenant une dose thérapeutique d'un inhibiteur de HSP90 hétérocyclique de synthèse, l'activité de l'inhibiteur de HSP90 étant sensiblement indépendante de la multirésistance aux médicaments. Dans un mode de réalisation, l'activité de l'inhibiteur de HSP90 est sensiblement indépendante de l'expression de P-gp et MRP.